The initial success of the copyright undeniably transformed the drug landscape, but placing funds in companies primarily reliant on unbranded versions presents a challenging picture. Despite check here early earnings were impressive, the expiration of patents and the rise of discounted alternatives have weakened the customer base. Thus, a thorough